Board of Directors
Jay Lichter, PhD
Jay Lichter, PhD, is an entrepreneur and seasoned investor in the biotechnology and pharmaceutical arena with over 25 years of expertise in management, scientific research, and business development. He currently serves as president and CEO of COI Pharmaceuticals.
As managing director of Avalon Ventures, Dr. Lichter led investments in Afraxis, Carolus, Otonomy, Sova and Zacharon Pharmaceuticals. Dr. Lichter has served as CEO of many these companies, which has included leading both their business and scientific operations during the companies’ formative periods. He is on the board of directors for most of these companies and also served as Chairman of the Board of RQx, another Avalon company. He led the first life science investments for the Avalon IX portfolio, Sova Pharmaceuticals, and serves as its CEO and board member. He also led the investment in Aratana Therapeutics, where he serves as chairman of the board. Dr. Lichter serves as chairman of the board of Avelas Biosciences. Dr. Lichter is the inventor on over 260 patent and patent applications for six Avalon portfolio companies, including 78 issued patents. Dr. Lichter has been involved in licensing or merger and acquisition deals valued in excess of $1 billion.
Dr. Lichter held postdoctoral positions in Human Genetics at Yale University and pharmacogenetics at DuPont Merck Pharmaceutical Co. Dr. Lichter obtained his Ph.D. in biochemistry from the University of Illinois at Chicago, and a B.S. from the Univ. of Illinois at Urbana-Champaign.
Claus Kremoser, PhD
Claus Kremoser, Ph.D. joined Avelas Biosciences’ board of directors in May 2015. Dr. Kremoser is the co-founder and CEO of Phenex Pharmaceuticals AG. In December 2014 Phenex executed a $470 million transaction with Gilead Sciences on Phenex’s FXR NASH program. In addition, Dr. Kremoser has led numerous drug discovery partnerships for Phenex as well as implementing proprietary drug discovery programs on the targets RORgt and FXR.
Previously Dr. Kremoser served as Vice President of Corporate Development for LION Biosciences. He also served as a founding member of the German E&Y Life Science Practice where he co-authored the fourth and fifth editions of the European E&Y Biotech Report. He is currently a member of the BioRN board (Biotech Cluster Heidelberg) and communicates the benefits of combining science and entrepreneurship into “biobusiness”. Together with other leading German CEOs he is member of the “1% for the future” which aims in fostering political initiatives to build a new financing environment for high tech innovation in Europe and Germany.
Dr. Kremoser studied biochemistry at the Universities of Tübingen and Munich. He performed his Ph.D. thesis in the group of Dr. Friedrich Boenhoeffer at the Max-Planck Institute. Dr. Kremoser received his Ph.D. magna cum laude from the University of Tübingen.
Timothy Scott is co-founder and President of Pharmatek Laboratories, Inc. Mr. Scott also serves on the boards of a number of pharmaceutical startup companies, including Avelas Biosciences, Orphagen Pharmaceuticals, and Tega Pharmaceuticals. Mr. Scott is a member of the board of BIOCOM, a non-profit organization supporting the needs of the bio/pharma companies in Southern California. In the community, Mr. Scott serves as a trustee for the La Jolla Playhouse, a Tony-award winning regional theatre in La Jolla, California. Mr. Scott founded and chairs the Pharmatek Foundation, a non-profit organization that supports and encourages sponsored volunteerism of Pharmatek employees and others in the San Diego community. Mr. Scott earned his B.A. in Biochemistry from the University of California, San Diego. He earned his J.D. from the University of San Diego and is a member of the California Bar.
Andrei Petrov, PhD
Andrei Petrov Ph.D. is founder, CEO and managing partner of Inbio Ventures. He is a Russian scientist with a vast knowledge and 11 years of experience in molecular biology, cell biology and immunology. He is member of the board of Argos (Durham, NC) and enGene (Montreal, Canada).
He was member of the board of Affitech AS (Norway, Denmark) and co.don AG (Teltow, Germany).
Before Inbio Ventures was founded, Andrei Petrov gained extensive experience of 7 years in biopharmaceutical industry being heavily involved in all aspects of drug discovery and drug development. He served as chief scientific officer of International Biotechnology Center Generium far before the company was officially incorporated in 2011. His main responsibilities were spread from portfolio building and its comprehensive day-to-day management, including full set of related business development activities, to strategic planning of overall company’s development. These activities resulted in amazing evolving of a small start-up company to internationally recognized biopharmaceutical R&D Center with 40+ actively managed projects.
Carmine Stengone has more than 15 years of experience in the pharmaceutical and biotechnology industries, including positions in executive management, finance, strategic planning, corporate development, licensing, alliance management and venture funding.
Mr. Stengone joined Avelas Biosciences in January 2012 as chief business officer and became chief executive officer and a member of the board of directors in January 2014. During his time with Avelas, Mr. Stengone has led all business activities, including securing a series B financing to drive AVB-620 into clinical development. In addition to his responsibilities with Avelas, Mr. Stengone serves as senior vice president, business development for COI Pharmaceuticals. In his previous role as vice president of corporate development for Afraxis Holdings, Mr. Stengone led and executed a $187.5 million license agreement with Roche’s subsidiary, Genentech. Mr. Stengone was also co-founder and CEO of Afraxis, Inc., a spin-out company from Afraxis Holdings. Prior to joining Afraxis, he was with Phenomix Corporation as the senior director of business development and on the executive management team. Mr. Stengone has also worked at Anadys Pharmaceuticals and Johnson & Johnson Pharmaceutical Research and Development.
Mr. Stengone received his MBA from the Johnson Graduate School of Management at Cornell University. He also holds a M.S. degree in organic chemistry from Duke University and a B.S. in chemistry from Wake Forest University.